Multiple-Gene Sequencing IDs Mutations in Non-BRCA Carriers

Share this content:
Multiple-Gene Sequencing IDs Mutations in Non-BRCA Carriers
Multiple-Gene Sequencing IDs Mutations in Non-BRCA Carriers

(HealthDay News) — A considerable number of women testing negative for BRCA1/2 may have pathogenic mutations in other genes, according to a study published online April 14 in the Journal of Clinical Oncology.

Allison W. Kurian, MD, from the Stanford University School of Medicine in California, and colleagues investigated the performance of a customized germline-DNA sequencing panel for cancer-risk assessment. DNA was extracted from samples taken from patients referred for clinical BRCA1/2 testing from 2000 to 2012 and frozen at −80 degrees Celsius. 

The entire coding regions, exon-intron boundaries, and pathogenic variants in other regions were sequenced for 42 genes with known cancer risk associations in samples from 198 women, including 174 with breast cancer. Fifty-seven of the women harbored germline BRCA1/2 mutations.

RELATED: Breast Cancer Resource Center

The researchers observed full concordance for BRCA1/2 analysis with prior testing. Among 141 women without BRCA1/2 mutations, 16 pathogenic variants (11.4%) were identified in nine genes (ATM, BLM, CDH1, CDKN2A, MUTYH, MLH1, NBN, PRSS1, and SLX4). 

Fifteen pathogenic variants identified in 14 participants warranted a potential change in care; these participants were invited for targeted screening recommendations, facilitating colonoscopy-based early detection and removal of a tubular adenoma. 

On average, among the 42 genes, participants carried 2.1 variants of unknown significance.

"Our study demonstrates an early signal for the clinical relevance of multiple-gene sequencing and provides a strong rationale for future research to define its most effective use," the researchers wrote.

Several authors disclosed financial ties to the biotechnology industry.


  1. Kurian AW, Hare EE, Mills MA, et al. Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. J Clin Oncol. 2014;doi: 10.1200/JCO.2013.53.6607.

    Related Resources

    You must be a registered member of Cancer Therapy Advisor to post a comment.

    Sign Up for Free e-newsletters

    Regimen and Drug Listings


    Bone Cancer Regimens Drugs
    Brain Cancer Regimens Drugs
    Breast Cancer Regimens Drugs
    Endocrine Cancer Regimens Drugs
    Gastrointestinal Cancer Regimens Drugs
    Gynecologic Cancer Regimens Drugs
    Head and Neck Cancer Regimens Drugs
    Hematologic Cancer Regimens Drugs
    Lung Cancer Regimens Drugs
    Other Cancers Regimens
    Prostate Cancer Regimens Drugs
    Rare Cancers Regimens
    Renal Cell Carcinoma Regimens Drugs
    Skin Cancer Regimens Drugs
    Urologic Cancers Regimens Drugs